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SUMMARY
Anauditoftherapeuticdrugmonitoring (TDM)ofanticonvulsants wasperformnedtoassess
both its use and misuse in the managetnent ofpatients with epilepsy. Over afour week
period all samples received for phenytoin, carbatnazepine, sodium valproate an1d
phenobarbitone assays were included in the audit. The aims were to establish the soulrce
ofthe specimens, the reasonsfor the requests and to ascertain what actioni, ifany, would
be taken when the result ofthe assay was provided. A total of 163 separate assays were
perforrmed over thefour week period (43 phenvtoin, 74 carbamazepine, 41 valproate, 5
phenobarbitone). Only 18.7%ofacllrequestsoriginatedfromntheadultneurologydepartment.
The vast majority of tests had been ordered by junior medical staff (onlv 10% bv
consultants)andapproximately50% were 'routine' withnosatisfactoryclinlicalreasonfot
the request offered. There was a tendency to manipulate prescribed doses oni the basis *4f
drug levels alone without taking the clinical picture into consideration. These resIllts
demonstrate a general ignorance, especially amongstjuniormtiedicalstaff (fthe value of
TDM ofanticonvulsants, anid reiniforc-e the need for both an educative anid intetprelive
service to be provided bv the Chemical Pathology Department.
INTRODUCTION
Therapeutic drug monitoring (TDM) may be defined as the use ofdrug measurements in
body fluids as an aid to the management of patients receiving drug therapy for the cure,
alleviation orprevention ofdisease.' Several clinical studies have demonstrated benefit in
utilising TDM to individualise dosing regimens in patients on anticonvulsant drugs where
pharmacological response is not so easily established by clinical means or laboratory
markers.2'` Although TDM assists in the optimisation of anticonvulsant therapy, clinical
and othercriteria are important and TDM should neverbe used as the sole basis formaking
dosage adjustments.' However there are few prospective studies showing any substantial
long term benefit to patients from TDM ofanticonvulsant, and some ofthe anticonvulsant
drugs do not fulfil the criteria that are necessary for valid TDM. These criteria include:
a). a narrow therapeutic index.
b). a close concentration-effect relationship.
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c). absence ofclinical markers ofeffect. (Ifthe desired effect can be quantified by simple
clinical measurements TDM are of little benefit.)
d). poor correlation between dose and plasma concentration or effect.
There is an impression ofa general ignorance, especially amongjunior medical staff, with
regard to the value and use ofTDM of anticonvulsants and this has led to a large increase
in demand for these tests and subsequent laboratory workload over the past 10-15 years.
Indeed some reviews ofTDM, in general, point to misuse and misapplication and a failure
to apply the criteria for effective TDM.6 In today's stringent financial climate there is also
the issue of costs versus benefits to patients. Some reviews suggest that an education
system, with help in interpretation of results to the prescribing doctor should be a high
priority in centres performing these assays.7 The concept of normal therapeutic ranges is
controversial as frequently patients with epilepsy will have satisfactory control ofseizures
atlevels below the normally acceptedtherapeutic range Iwhile others require concentrations
in excess of the normal therapeutic range without displaying toxic effects.9'0 In view of
these factors there is the potential for misuse and misinterpretation of TDM of
anticonvulsants. The monitoring ofpatients whose seizures are well controlled and who are
free of toxic side effects is also questionable.
It is because ofthese factors that this audit was performed to assess TDM ofanticonvulsants
in a teaching hospital, to establish why the test was requested, to assess the impact of the
result on patient management and whether to attempt to provide an educative and
interpretive service.
PATIENTS AND METHODS
Overa four week period in June 1993, all samples received by the biochemistry laboratory
of the Royal Group of Hospitals, Belfast, for TDM of phenytoin, carbamazepine, sodium
valproate and phenobarbitone were audited. The Royal Group of Hospitals is a major
teaching hospital, with amongstotherdisciplines, an Accident and Emergency department,
a respiratory intensive care unit, a paediatric department and the regional neurology and
neurosurgery service. The source of the samples was identified and the drug assays were
all performed using the establishedFPIA (fluorescence polarisation immunoassay) method
(Abbott Diagnostics, Maidenhead, Berkshire, UK). Anticonvulsant assays were performed
inbatches on a twice weekly basis and the need for emergency assays at other times
(including those outside normal laboratory working hours) was assessed by the Chemical
Pathology registrar.
When the assay results were available the ward, out-patient department or general
practitioner was phoned by the registrar (PCS) and the doctor who had ordered the test was
contacted (e.g. ifa senior house officer had ordered a test on a consultant's instructions, the
consultant was contacted). The reason for the request was ascertained and the result ofthe
assay given with the 'normal' therapeutic range, and the doctor was asked in view of this,
as to what action, ifany, would be taken in the prescribed dose for the patient. Subsequently
he was given information on the interpretation of the result. All requests were allocated to
one of 7 groups on the basis of the stated reason for the request, thus:
I. No specific indication ('routine'). The patient's epilepsy was well controlled and there
was no clinical suspicion of toxicity.
2. A recent increase in the numberofseizures, before which control had been reasonable,
or continuing seizures (?compliance problem or too low a prescribed dose).
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3. Recent change in dose of the medication, or had recently been commenced on the
medication.
4. Possible symptoms and signs of toxicity and a drug level requested to verify this.
5. Status epilepticus.
6. Patient on potentially interacting drugs.
7. Overdose of anticonvulsant.
RESULTS
Over the four week period a total of 139 samples were received. Four of these were
emergency samples which were performed outside ofnormal laboratory hours by the on-
call technician (two overdoses in adults, one child with probable toxicity and anotherwith
status epilepticus in the children's intensive care unit). One hundred and fifteen (115)
patients were on monotherapy to control theirepilepsy while the other 24 patients were on
two medications requiring the analysis of two separate anticonvulsant drugs, making a
grand total of 163 separate assays (43 phenytoin, 74 carbamazepine, 41 valproate and 5
phenobarbitone). The sources of the requests are given in Table I and the reasons for the
requests in Table II. Ten percent of the total hospital requests had been ordered by
consultants, 22% by senior registrars/registrars and 68% by senior house officers. 1 1.5%
ofpatient requests originated from general practice.
Phenytoin (26.4% of all requests)
In 20 routine assays (47% ofphenytoin requests) in patients who were clinically well with
no signs oftoxicity, 18 out of20 (90%) lay in the normal therapeutic range (10-20 mg/I),
one was lower(6.4 mg/l), but nochange in dosage was made, and one was higher(28.3 mg/l):
TABLE I
Sources ofrequestsfor TDM ofanticonvulsants
Source Number ofPatients
Medical Wards 21 (15%)
Surgical Wards 5 (3.6%)
Medical Outpatients 18 (12.9%)
Neurology Outpatients 15 (10.8%)
Neurology Inpatients 11 (7.9%)
Intensive Care Unit 5 (3.6%)
Childrens Hospital Inpatients 28 (20.1%)
Childrens Hospital Outpatients 12 (8.6%)
Accident and Emergency 4 (2.9%)
Other Hospitals 4 (2.9%)
General Practice 16 (11.5%)
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in this case a dose reduction was made even though the patient had no toxic symptoms. In
the seven assays performed due to recent increased episodes of seizures, six out of seven
displayed levels lower than the therapeutic range in keeping with either a compliance
problem or too low a prescribed dose (all six either confronted the patient with regard to
compliance orincreased the prescribed dose), the otherresult was in the therapeutic range.
In six cases ofsuspected toxicity, fourwere in the toxic range and theothertwo were in the
upper normal range: in all cases a dose reduction was made. Five out ofthe six assays for
status epilepticus were in a single patient receiving intravenous phenytoin.
TABLE II
Reasonsfor requestsfor TDM ofthe different anticonvulsants
Reasonfor request Phenytoin Carbamazepine Valproate Phenobarbitone
1. Routine level 20 (46.5%) 36 (48.6%) 26 (63.4%) 2 (40%)
2. Continuing seizures 7 (16.3%) 19 (25.7%) 12 (29.3%) 3 (60%)
3. Recent dose change 2 (4.7%) 8 (10.8%) 1 (2.4%) 0
4. Possible toxicity 6 (14.0%) 9 (12.2%) 1 (2.4%) 0
5. Status Epilepticus 6 (14.0%) 0 0 0
6. Interacting Drugs 0 1 (1.4%) 0 0
7. Overdose 2 (4.7%) 1 (1.4%) 1 (2.4%) 0
Carbamazepine (45.3% of all requests)
In 36 routine assays (49% ofcarbamazepine requests), 29 were in the normal therapeutic
range (8-12mg/I), fourwere lowerwith noincrease indosebeingprescribedandthreewere
above the normal range (two patients had their dose reduced even though they were well
with notoxic symptoms). In 19patients with recentseizures, 14werebelowthe therapeutic
range and the dose was either increased orthe patient challenged regarding compliance. In
the nine suspected toxicities, seven out ofnine were in the 'toxic' range with the othertwo
at the upper limit of the normal range: all doses were reduced.
Sodium Valproate (25.2% of all requests)
Out of26routine assays (63% ofvalproate requests), 13 were in the normal range, ten were
below the therapeutic range (eight ofthese patients were either challenged with regard to
compliance or had their prescribed doses increased) and three patients had valproate
concentrations higherthan the therapeutic range (all hadtheirprescribed dose reduced). In
the 12 patients with recent increase in seizures, six had levels lower than the normal
therapeutic range and the other six lay in the therapeutic range; the six with the low levels
had theirdoses increased. The one patient with suspected toxicity had a level in the normal
range and the dose was reduced. The one overdose patient had a level of 610 mg/I but
remained perfectly well with apparently no side effects.
Phenobarbitone (3.1 % of requests)
Two routine (40%) checks had normal therapeutic levels, and of the three patients with
recent increasing seizures, two had levels below the therapeutic range and doses were
increased: one had a normal therapeutic level but nonetheless the prescribed dose was also
increased.
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DISCUSSION
This audit illustrates that there is misunderstanding with regard to the concept and uses of
TDM ofanticonvulsant drugs. Ofparticular interest is the fact that the vast majority oftests
were ordered byjuniormedical staffandacomparatively smallnumber(I8.7% ofrequests)
came from the adult neurology in-patient andout-patient departments, despite the fact that
this department manages most patients with epilepsy. This most probably reflects their
greater understanding ofthe usefulness ofTDM indifferentcircumstances. Alsoofinterest
is the fact that for approximately halfofrequests there was no specific indication for drug
level measurement. Only one ofthis type ofrequest came from the neurology department.
It appears that there is little potential benefit to the patient in this category as the majority
of levels lie within the normal therapeutic range. Of more concern is that in patients with
well controlled epilepsy, without toxic side effects, but with drug levels above the
therapeutic range, there was atendency to 'treat' the drug level andreduce the dose, despite
the fact that some of these patients may require higher plasma concentrations to control
their seizures. From this audit we can also see that most of those with either recent
increasing incidence of seizures or with suspected toxicity displayed the appropriate low
orhigh levels respectively andthatclinicaljudgement was accurate. The notable exception
to all ofthe above is sodium valproate. This drug displays a wide circadian variation with
plasmaconcentrations varying by as much as 100% across the dosage interval. The normal
therapeutic ortargetrange isdifficult todefine, plasmaconcentrations are nobetteraguide
to clinical response than is dose, and toxic effects show no clear relationship with level.
These facts are borne out by our results and it is suggested that routine monitoring should
not be practised and is, in fact, potentially misleading." 2
Monitoring of carbamazepine can be of use in some circumstances. The major problem
with its measurement relates to its metabolism in the liver to carbamazepine-10, 11-
epoxide, which is active but is not measured in most routine assays, including our own.
However, the active metabolite can be measured using HPLC (high performance liquid
chromatography), but this is not routinely available in most biochemistry laboratories and
is expensive and time consuming to perform. Monitoring of carbamazepine is also
complicated by individual pharmacodynamic variability; it induces its own metabolism
and its metabolism can be altered by otheranticonvulsants. The dosage ofcarbamazepine
is a poor guide to plasma concentration and TDM is useful when seizure control is
difflcult.1 ,4
Ofall the anticonvulsants phenytoin appears to be the most useful to monitor.'5 It displays
dosedependent pharmacokinetics and thehepatic system which metabolises itcan become
saturated, meaning that there is a non-linear relationship between dose and plasma
concentrationwiththesaturationlevelsvaryingbetweenindividuals.Thenormaltherapeutic
range has been designated 10-20 mg/l but some patients are controlled both at lower and
higher levels and the prescribed dose of phenytoin should not be reduced on the basis of
a high level if the patient is free from side effects.
With phenobarbitone, tolerance can develop on longer term therapy and there is a poor
correlationbetweenplasmaconcentrationandadverseeffects,andverylowlevelscanhave
significant antiepileptic effects. There is a potential interaction with valproate which can
lead to high phenobarbitone levels but in general TDM is not of much use except in
children.
The results ofthis auditdemonstrate an apparentlackofknowledgewithregardtothevalue
and use ofTDM ofanticonvulsants and a tendency to perform levels as a matterofroutine.
Ther-e is also a tendency to manipulate drug doses on the results of plasma levels alone,
© The Ulster Medical Society, 1995.
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aiming to establish the patient in the centre ofthe normal therapeutic range without taking
the whole clinical picture into consideration. It is widely recognised that phenytoin is the
most helpful drug tomonitorbecause ofits saturation kinetics, and thatmonitoring sodium
valproate offers little reliable information and in fact can be misleading. The need to
monitorpatients whose seizures are well controlled is debatable and therapeutic decisions
should neverbe based solely on drug concentrations. TDM can be useful in the assessment
ofnon-compliance. For instance, repeatedly zero plasma concentrations in a patient who
is 'well controlled' probably indicates misdiagnosis or that therapy is no longer required.
The 'normal' therapeutic range should be used for guidance only with the knowledge that
some patients may be well controlled at lower or higher levels and similarly patients can
display toxicity in the normal therapeutic range. Patients on twoormore medications merit
more regularmonitoring as there is potential fordrug interactions and it can be difficult to
tell which drug is causing possible toxic side effects or is not being prescribed in an
appropriate dose. Education provided by the laboratory into the interpretation ofresults is
essential and it is envisaged that guidelines will be drawn up to help medical staff. Cost
effectiveness is of major importance in today's climate and the question should be asked
"Isknowingadruglevelgoingtohelpmeinthemanagementofthispatientatthisparticular
time?"
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